Overview

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
Phase:
Phase 3
Details
Lead Sponsor:
Ipsen
Treatments:
Angiopeptin
Lanreotide
Somatostatin